Clinical Trials
7 trialsNCT05703971 2026-06-03
Acclaim-3
Genprex, Inc.
Phase 1/2 Recruiting
NCT07227597 2026-05-28
MK-6070-003
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05680922 2026-03-24
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
Legend Biotech USA Inc
Phase 1 Active not recruiting
NCT06610734 2026-02-09
SKY
Sichuan University
Phase 2 Recruiting
NCT05856695 2025-09-24
TAXIO
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Active not recruiting
NCT06982287 2025-07-08
A Retrospective Real-World Study on the Efficacy and Safety of Anlotinib Hydrochloride Combined With Immunotherapy Maintenance Therapy Following Standard Chemoimmunotherapy for ES-SCLC (ALTER-L059)
Sir Run Run Shaw Hospital
Not yet recruiting
NCT07022301 2025-06-15
Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy
First Affiliated Hospital of Wannan Medical College
Phase 2 Not yet recruiting